Cargando…

Primary central nervous system lymphoma in the United States, 1975–2017

BACKGROUND: Primary central nervous system lymphoma (PCNSL) has received more attention because of an inferior prognosis. Less is known about the incidence rate, histological type, and survival rate of PCNSL, especially in the 2010s. METHODS: Data of PCNSL from the Surveillance, Epidemiology, and En...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Chenglan, Wang, Jing, Zhou, Min, Xu, Jing-Yan, Chen, Bing, Wan, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793121/
https://www.ncbi.nlm.nih.gov/pubmed/35096360
http://dx.doi.org/10.1177/20406207211066166
_version_ 1784640527009841152
author Lv, Chenglan
Wang, Jing
Zhou, Min
Xu, Jing-Yan
Chen, Bing
Wan, Yuan
author_facet Lv, Chenglan
Wang, Jing
Zhou, Min
Xu, Jing-Yan
Chen, Bing
Wan, Yuan
author_sort Lv, Chenglan
collection PubMed
description BACKGROUND: Primary central nervous system lymphoma (PCNSL) has received more attention because of an inferior prognosis. Less is known about the incidence rate, histological type, and survival rate of PCNSL, especially in the 2010s. METHODS: Data of PCNSL from the Surveillance, Epidemiology, and End Results (SEER) registry database (SEER 9 registries and SEER 18 registries) were used. Incidence was estimated by age, gender, race, site, and histological type. Trends were analyzed using joinpoint regression and described as annual percent change (APC) and average annual percent change (AAPC). Five-year overall survival estimates were compared using log-rank tests. RESULTS: Most PCNSL occurred in the brain, followed by the spinal cord. The most frequent histological type of PCNSL was diffuse large B-cell lymphoma, followed by marginal zone lymphoma. Incidence rate increased from 0.1/100,000 to 0.5/100,000 with an AAPC of 5.3% from 1975 to 2017. Incidence rates varied greatly between the younger and older age population. The 5-year overall survival rates in SEER 9 registries and SEER 18 registries were 30.5% and 37.4%, respectively. Even though the 5-year overall survival rate significantly increased from 27.9% for the 1975–1979 time period to 44.8% for the 2010–2017 time period, survival benefit could not be expected for patients ⩾60 years. The 5-year survival rate for elderly patients was about 30% in the 2010s. CONCLUSION: With aging, the incidence of PCNSL in the elderly is increased. Over the past decade, no advances have been made in the treatment of elderly PCNSL. Prospective trials with PCNSL are warranted to improve the survival of elderly patients.
format Online
Article
Text
id pubmed-8793121
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-87931212022-01-28 Primary central nervous system lymphoma in the United States, 1975–2017 Lv, Chenglan Wang, Jing Zhou, Min Xu, Jing-Yan Chen, Bing Wan, Yuan Ther Adv Hematol Original Research BACKGROUND: Primary central nervous system lymphoma (PCNSL) has received more attention because of an inferior prognosis. Less is known about the incidence rate, histological type, and survival rate of PCNSL, especially in the 2010s. METHODS: Data of PCNSL from the Surveillance, Epidemiology, and End Results (SEER) registry database (SEER 9 registries and SEER 18 registries) were used. Incidence was estimated by age, gender, race, site, and histological type. Trends were analyzed using joinpoint regression and described as annual percent change (APC) and average annual percent change (AAPC). Five-year overall survival estimates were compared using log-rank tests. RESULTS: Most PCNSL occurred in the brain, followed by the spinal cord. The most frequent histological type of PCNSL was diffuse large B-cell lymphoma, followed by marginal zone lymphoma. Incidence rate increased from 0.1/100,000 to 0.5/100,000 with an AAPC of 5.3% from 1975 to 2017. Incidence rates varied greatly between the younger and older age population. The 5-year overall survival rates in SEER 9 registries and SEER 18 registries were 30.5% and 37.4%, respectively. Even though the 5-year overall survival rate significantly increased from 27.9% for the 1975–1979 time period to 44.8% for the 2010–2017 time period, survival benefit could not be expected for patients ⩾60 years. The 5-year survival rate for elderly patients was about 30% in the 2010s. CONCLUSION: With aging, the incidence of PCNSL in the elderly is increased. Over the past decade, no advances have been made in the treatment of elderly PCNSL. Prospective trials with PCNSL are warranted to improve the survival of elderly patients. SAGE Publications 2022-01-23 /pmc/articles/PMC8793121/ /pubmed/35096360 http://dx.doi.org/10.1177/20406207211066166 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Lv, Chenglan
Wang, Jing
Zhou, Min
Xu, Jing-Yan
Chen, Bing
Wan, Yuan
Primary central nervous system lymphoma in the United States, 1975–2017
title Primary central nervous system lymphoma in the United States, 1975–2017
title_full Primary central nervous system lymphoma in the United States, 1975–2017
title_fullStr Primary central nervous system lymphoma in the United States, 1975–2017
title_full_unstemmed Primary central nervous system lymphoma in the United States, 1975–2017
title_short Primary central nervous system lymphoma in the United States, 1975–2017
title_sort primary central nervous system lymphoma in the united states, 1975–2017
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793121/
https://www.ncbi.nlm.nih.gov/pubmed/35096360
http://dx.doi.org/10.1177/20406207211066166
work_keys_str_mv AT lvchenglan primarycentralnervoussystemlymphomaintheunitedstates19752017
AT wangjing primarycentralnervoussystemlymphomaintheunitedstates19752017
AT zhoumin primarycentralnervoussystemlymphomaintheunitedstates19752017
AT xujingyan primarycentralnervoussystemlymphomaintheunitedstates19752017
AT chenbing primarycentralnervoussystemlymphomaintheunitedstates19752017
AT wanyuan primarycentralnervoussystemlymphomaintheunitedstates19752017